Skip to main content
SpringerLink
Log in

Nuclear Medicine in Evaluation and Therapy of Nodular Thyroid

  • Chapter
  • First Online:
Thyroid Nodules

Part of the book series: Contemporary Endocrinology ((COE))

Abstract

In current practice, thyroid scintigraphy is predominantly used for thyroid nodules in patients with subnormal TSH. We present radiopharmaceuticals used for imaging and therapy and describe imaging procedures and interpretation of findings. Differences between European and US practices are addressed. Patient preparation and instructions prior to nuclear thyroid imaging and therapy are described. We discuss the current indications for radioiodine therapy of benign nodular disease, how the administered dosage is determined, and the results and complications of radioiodine treatment. Nuclear medicine evaluation of nodular thyroid in children is addressed briefly. The potential role of nuclear medicine imaging in the differentiation of benign from malignant follicular lesions is reviewed. Lastly, how to approach incidental finding of increased uptake of 18F-FDG in a thyroid nodule is discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Becker DV, Sawin CT. Radioiodine and thyroid disease: the beginning. Semin Nucl Med. 1996;26(3):155–64.

    Article  CAS  PubMed  Google Scholar 

  2. Sawin CT, Becker DV. Radioiodine and the treatment of hyperthyroidism: the early history. Thyroid. 1997;7(2):163–76.

    Article  CAS  PubMed  Google Scholar 

  3. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L. American Thyroid Association Management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2015;26(1):1–133.

    Article  Google Scholar 

  4. Burch HB, Burman KD, Cooper DS, Hennessey JV, Vietor NO. A 2015 survey of clinical practice patterns in the management of thyroid nodules. J Clin Endocrinol Metab. 2016;101(7):2853–62.

    Article  CAS  PubMed  Google Scholar 

  5. Bennedbaek FN, Perrild H, Hegedus L. Diagnosis and treatment of the solitary thyroid nodule. Results of a European survey. Clin Endocrinol. 1999;50(3):357–63.

    Article  CAS  Google Scholar 

  6. Bennedbaek FN, Hegedus L. Management of the solitary thyroid nodule: results of a North American survey. J Clin Endocrinol Metab. 2000;85(7):2493–8.

    Article  CAS  PubMed  Google Scholar 

  7. Gharib H, Papini E, Garber JR, Duick DS, Harrell RM, Hegedus L, et al. American Association of Clinical Endocrinologists, American College of Endocrinology, and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules – 2016 update. Endocr Pract. 2016;22(5):622–39.

    PubMed  Google Scholar 

  8. Silberstein EB, Alavi A, Balon HR, Clarke SE, Divgi C, Gelfand MJ, et al. The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0. J Nucl Med. 2012;53(10):1633–51.

    Article  PubMed  Google Scholar 

  9. ACR–SNM–SPR Practice guideline for the performance of thyroid scintigraphy and uptake measurements. http://snmmi.files.cms-plus.com/docs/Thyroid_Scintigraphy_1382732120053_10.pdf2009, 2009.

  10. Crawford DC, Flower MA, Pratt BE, Hill C, Zweit J, McCready VR, et al. Thyroid volume measurement in thyrotoxic patients: comparison between ultrasonography and iodine-124 positron emission tomography. Eur J Nucl Med. 1997;24(12):1470–8.

    Article  CAS  PubMed  Google Scholar 

  11. Eschmann SM, Reischl G, Bilger K, Kupferschlager J, Thelen MH, Dohmen BM, et al. Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET. Eur J Nucl Med Mol Imaging. 2002;29(6):760–7.

    Article  CAS  PubMed  Google Scholar 

  12. Gabler AS, Kuhnel C, Winkens T, Freesmeyer M. Assessment of minimum 124I activity required in uptake measurements before radioiodine therapy for benign thyroid diseases. J Nucl Med. 2016;57(8):1201–6.

    Article  PubMed  Google Scholar 

  13. Ruhlmann M, Jentzen W, Ruhlmann V, Pettinato C, Rossi G, Binse I, et al. High level of agreement between pretherapeutic 124I PET and intratherapeutic 131I images in detecting iodine-positive thyroid cancer metastases. J Nucl Med. 2016;57(9):1339–42.

    Article  PubMed  Google Scholar 

  14. McDougall IR. Thyroid disease in clinical practice. US: Springer; 1992.

    Book  Google Scholar 

  15. Miller JM, Hamburger JI. The thyroid scintigram. I. The hot nodule. Radiology. 1965;84:66–74.

    Article  CAS  PubMed  Google Scholar 

  16. Chami R, Moreno-Reyes R, Corvilain B. TSH measurement is not an appropriate screening test for autonomous functioning thyroid nodules: a retrospective study of 368 patients. Eur J Endocrinol. 2014;170(4):593–9.

    Article  CAS  PubMed  Google Scholar 

  17. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Nagai GR, Pitts WC, Basso L, Cisco JA, McDougall IR. Scintigraphic hot nodules and thyroid carcinoma. Clin Nucl Med. 1987;12(2):123–7.

    Article  CAS  PubMed  Google Scholar 

  19. Mirfakhraee S, Mathews D, Peng L, Woodruff S, Zigman JM. A solitary hyperfunctioning thyroid nodule harboring thyroid carcinoma: review of the literature. Thyroid Res. 2013;6(1):7.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Tonacchera M, Pinchera A, Vitti P. Assessment of nodular goitre. Best Pract Res Clin Endocrinol Metab. 2010;24(1):51–61.

    Article  CAS  PubMed  Google Scholar 

  21. Belfiore A, La Rosa GL, La Porta GA, Giuffrida D, Milazzo G, Lupo L, et al. Cancer risk in patients with cold thyroid nodules: relevance of iodine intake, sex, age, and multinodularity. Am J Med. 1992;93(4):363–9.

    Article  CAS  PubMed  Google Scholar 

  22. Carnell NE, Valente WA. Thyroid nodules in Graves’ disease: classification, characterization, and response to treatment. Thyroid. 1998;8(7):571–6.

    Article  CAS  PubMed  Google Scholar 

  23. Belfiore A, Garofalo MR, Giuffrida D, Runello F, Filetti S, Fiumara A, et al. Increased aggressiveness of thyroid cancer in patients with Graves’ disease. J Clin Endocrinol Metab. 1990;70(4):830–5.

    Article  CAS  PubMed  Google Scholar 

  24. Kraimps JL, Bouin-Pineau MH, Mathonnet M, De Calan L, Ronceray J, Visset J, et al. Multicentre study of thyroid nodules in patients with Graves’ disease. Br J Surg. 2000;87(8):1111–3.

    Article  CAS  PubMed  Google Scholar 

  25. Joven MH, Anderson RJ. Marine-Lenhart syndrome. Endocrine. 2015;49(2):570–1.

    Article  CAS  PubMed  Google Scholar 

  26. Charkes ND. Graves’ disease with functioning nodules (Marine-Lenhart syndrome). J Nucl Med. 1972;13(12):885–92.

    CAS  PubMed  Google Scholar 

  27. Uludag M, Aygun N, Ozel A, Yener Ozturk F, Karasu R, Ozguven BY, et al. A rare presentation of autonomously functioning papillary thyroid cancer: malignancy in Marine-Lenhart syndrome nodule. Case Rep Surg. 2016;2016:5. 8740405

    Google Scholar 

  28. Kusic Z, Becker DV, Saenger EL, Paras P, Gartside P, Wessler T, et al. Comparison of technetium-99m and iodine-123 imaging of thyroid nodules: correlation with pathologic findings. J Nucl Med. 1990;31(4):393–9.

    CAS  PubMed  Google Scholar 

  29. Reschini E, Ferrari C, Castellani M, Matheoud R, Paracchi A, Marotta G, et al. The trapping-only nodules of the thyroid gland: prevalence study. Thyroid. 2006;16(8):757–62.

    Article  PubMed  Google Scholar 

  30. Garberoglio S, Testori O. Role of nuclear medicine in the diagnosis of benign thyroid diseases. Front Horm Res. 2016;45:24–36.

    Article  PubMed  Google Scholar 

  31. Hayes AA, Akre CM, Gorman CA. Iodine-131 treatment of Graves’ disease using modified early iodine-131 uptake measurements in therapy dose calculations. J Nucl Med. 1990;31(4):519–22.

    CAS  PubMed  Google Scholar 

  32. Higgins HP, Ball D, Eastham S. 20-M in 99mTc thyroid uptake: a simplified method using the gamma camera. J Nucl Med. 1973;14(12):907–11.

    CAS  PubMed  Google Scholar 

  33. Smith JJ, Croft BY, Brookeman VA, Teates CD. Estimation of 24-hour thyroid uptake of I-131 sodium iodide using a 5-minute uptake of technetium-99m pertechnetate. Clin Nucl Med. 1990;15(2):80–3.

    Article  CAS  PubMed  Google Scholar 

  34. Czepczynski R. Nuclear medicine in the diagnosis of benign thyroid diseases. Nucl Med Rev Cent East Eur. 2012;15(2):113–9.

    PubMed  Google Scholar 

  35. Romney BM, Nickoloff EL, Esser PD, Alderson PO. Radionuclide administration to nursing mothers: mathematically derived guidelines. Radiology. 1986;160(2):549–54.

    Article  CAS  PubMed  Google Scholar 

  36. Leide-Svegborn S, Ahlgren L, Johansson L, Mattsson S. Excretion of radionuclides in human breast milk after nuclear medicine examinations. Biokinetic and dosimetric data and recommendations on breastfeeding interruption. Eur J Nucl Med Mol Imaging. 2016;43(5):808–21.

    Article  CAS  PubMed  Google Scholar 

  37. Mountford PJ, Coakley AJ. A review of the secretion of radioactivity in human breast milk: data, quantitative analysis and recommendations. Nucl Med Commun. 1989;10(1):15–27.

    Article  CAS  PubMed  Google Scholar 

  38. Brzozowska M, Roach PJ. Timing and potential role of diagnostic I-123 scintigraphy in assessing radioiodine breast uptake before ablation in postpartum women with thyroid cancer: a case series. Clin Nucl Med. 2006;31(11):683–7.

    Article  PubMed  Google Scholar 

  39. Sisson JC, Freitas J, McDougall IR, Dauer LT, Hurley JR, Brierley JD, et al. Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I: practice recommendations of the American Thyroid Association. Thyroid. 2011;21(4):335–46.

    Article  PubMed  Google Scholar 

  40. Ross. 2016 American Thyroid Association guidelines for diagnosis and Management of Hyperthyroidism and other causes of thyrotoxicosis. Access date 9/11/2016. http://online.liebertpub.com/doi/pdfplus/10.1089/thy.2016.0229, 2016.

  41. Nygaard B, Hegedus L, Nielsen KG, Ulriksen P, Hansen JM. Long-term effect of radioactive iodine on thyroid function and size in patients with solitary autonomously functioning toxic thyroid nodules. Clin Endocrinol. 1999;50(2):197–202.

    Article  CAS  Google Scholar 

  42. Reinhardt MJ, Joe A, von Mallek D, Zimmerlin M, Manka-Waluch A, Palmedo H, et al. Dose selection for radioiodine therapy of borderline hyperthyroid patients with multifocal and disseminated autonomy on the basis of 99mTc-pertechnetate thyroid uptake. Eur J Nucl Med Mol Imaging. 2002;29(4):480–5.

    Article  CAS  PubMed  Google Scholar 

  43. Erickson D, Gharib H, Li H, van Heerden JA. Treatment of patients with toxic multinodular goiter. Thyroid. 1998;8(4):277–82.

    Article  CAS  PubMed  Google Scholar 

  44. Bransom CJ, Talbot CH, Henry L, Elemenoglou J. Solitary toxic adenoma of the thyroid gland. Br J Surg. 1979;66(8):592–5.

    Article  CAS  PubMed  Google Scholar 

  45. Vidal-Trecan GM, Stahl JE, Eckman MH. Radioiodine or surgery for toxic thyroid adenoma: dissecting an important decision. A cost-effectiveness analysis. Thyroid. 2004;14(11):933–45.

    Article  PubMed  Google Scholar 

  46. Huysmans DA, Corstens FH, Kloppenborg PW. Long-term follow-up in toxic solitary autonomous thyroid nodules treated with radioactive iodine. J Nucl Med. 1991;32(1):27–30.

    CAS  PubMed  Google Scholar 

  47. Ceccarelli C, Bencivelli W, Vitti P, Grasso L, Pinchera A. Outcome of radioiodine-131 therapy in hyperfunctioning thyroid nodules: a 20 years’ retrospective study. Clin Endocrinol. 2005;62(3):331–5.

    Article  CAS  Google Scholar 

  48. Ceccarelli C, Antonangeli L, Brozzi F, Bianchi F, Tonacchera M, Santini P, et al. Radioiodine 131I treatment for large nodular goiter: recombinant human thyrotropin allows the reduction of radioiodine 131I activity to be administered in patients with low uptake. Thyroid. 2011;21(7):759–64.

    Article  CAS  PubMed  Google Scholar 

  49. Braverman L, Kloos RT, Law B Jr, Kipnes M, Dionne M, Magner J. Evaluation of various doses of recombinant human thyrotropin in patients with multinodular goiters. Endocr Pract. 2008;14(7):832–9.

    Article  PubMed  Google Scholar 

  50. Nieuwlaat WA, Hermus AR, Sivro-Prndelj F, Corstens FH, Huysmans DA. Pretreatment with recombinant human TSH changes the regional distribution of radioiodine on thyroid scintigrams of nodular goiters. J Clin Endocrinol Metab. 2001;86(11):5330–6.

    Article  CAS  PubMed  Google Scholar 

  51. Hegedus L, Bonnema SJ, Bennedbaek FN. Management of simple nodular goiter: current status and future perspectives. Endocr Rev. 2003;24(1):102–32.

    Article  PubMed  Google Scholar 

  52. Iagaru A, McDougall IR. Treatment of thyrotoxicosis. J Nucl Med. 2007;48(3):379–89.

    CAS  PubMed  Google Scholar 

  53. Clerc J, Dagousset F, Izembart M, Jais JP, Heshmati HM, Alcais A, et al. Radioiodine therapy of the autonomous thyroid nodule in patients with or without visible extranodular activity. J Nucl Med. 1995;36(2):217–23.

    CAS  PubMed  Google Scholar 

  54. Rokni H, Sadeghi R, Moossavi Z, Treglia G, Zakavi SR. Efficacy of different protocols of radioiodine therapy for treatment of toxic nodular goiter: systematic review and meta-analysis of the literature. Int J Endocrinol Metab. 2014;12(2):e14424.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Stokkel MP, Handkiewicz Junak D, Lassmann M, Dietlein M, Luster M. EANM procedure guidelines for therapy of benign thyroid disease. Eur J Nucl Med Mol Imaging. 2010;37(11):2218–28.

    Article  PubMed  Google Scholar 

  56. Reschini E, Matheoud R, Canzi C, Castellani M, Galelli M, Ferrari C, et al. Dosimetry study in patients with autonomous thyroid nodule who are candidates for radioiodine therapy. J Nucl Med. 1999;40(11):1928–34.

    CAS  PubMed  Google Scholar 

  57. Berg GE, Michanek AM, Holmberg EC, Fink M. Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements. J Nucl Med. 1996;37(2):228–32.

    CAS  PubMed  Google Scholar 

  58. Hanscheid H, Canzi C, Eschner W, Flux G, Luster M, Strigari L, et al. EANM dosimetry committee series on standard operational procedures for pre-therapeutic dosimetry II. Dosimetry prior to radioiodine therapy of benign thyroid diseases. Eur J Nucl Med Mol Imaging. 2013;40(7):1126–34.

    Article  PubMed  Google Scholar 

  59. Horst W, Rosler H, Schneider C, Labhart A. 306 cases of toxic adenoma: clinical aspects, findings in radioiodine diagnostics, radiochromatography and histology; results of 131-I and surgical treatment. J Nucl Med. 1967;8(7):515–28.

    CAS  PubMed  Google Scholar 

  60. Meller J, Becker W. The continuing importance of thyroid scintigraphy in the era of high-resolution ultrasound. Eur J Nucl Med Mol Imaging. 2002;29(Suppl 2):S425–38.

    Article  PubMed  Google Scholar 

  61. Huysmans AK, Hermus RM, Edelbroek MA, Tjabbes T, Oostdijk, Ross HA, et al. Autoimmune hyperthyroidism occurring late after radioiodine treatment for volume reduction of large multinodular goiters. Thyroid. 1997;7(4):535–9.

    Article  CAS  PubMed  Google Scholar 

  62. Nygaard B, Faber J, Veje A, Hegedus L, Hansen JM. Transition of nodular toxic goiter to autoimmune hyperthyroidism triggered by 131I therapy. Thyroid. 1999;9(5):477–81.

    Article  CAS  PubMed  Google Scholar 

  63. Ron E, Doody MM, Becker DV, Brill AB, Curtis RE, Goldman MB, et al. Cancer mortality following treatment for adult hyperthyroidism. Cooperative Thyrotoxicosis Therapy Follow-up Study Group. JAMA. 1998;280(4):347–55.

    Article  CAS  Google Scholar 

  64. Holm LE, Hall P, Wiklund K, Lundell G, Berg G, Bjelkengren G, et al. Cancer risk after iodine-131 therapy for hyperthyroidism. J Natl Cancer Inst. 1991;83(15):1072–7.

    Article  CAS  PubMed  Google Scholar 

  65. Metso S, Auvinen A, Huhtala H, Salmi J, Oksala H, Jaatinen P. Increased cancer incidence after radioiodine treatment for hyperthyroidism. Cancer. 2007;109(10):1972–9.

    Article  CAS  PubMed  Google Scholar 

  66. Ryodi E, Metso S, Jaatinen P, Huhtala H, Saaristo R, Valimaki M, et al. Cancer incidence and mortality in patients treated either with RAI or thyroidectomy for hyperthyroidism. J Clin Endocrinol Metab. 2015;100(10):3710–7.

    Article  CAS  PubMed  Google Scholar 

  67. Francis GL, Waguespack SG, Bauer AJ, Angelos P, Benvenga S, Cerutti JM, et al. Management guidelines for children with thyroid nodules and differentiated thyroid cancer. Thyroid. 2015;25(7):716–59.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Pandey AK, Sharma SK, Sharma P, Gupta P, Kumar R. Development of a radiopharmaceutical dose calculator for pediatric patients undergoing diagnostic nuclear medicine studies. Indian J Nucl Med. 2013;28(2):75–8.

    Article  PubMed  PubMed Central  Google Scholar 

  69. Croom RD 3rd, Thomas CG Jr, Reddick RL, Tawil MT. Autonomously functioning thyroid nodules in childhood and adolescence. Surgery. 1987;102(6):1101–8.

    PubMed  Google Scholar 

  70. Wahl R. In: Braverman LE Cooer D, editors. The thyroid. Thyroid radionuclide uptake and imaging studies. 10th ed. Philadelphia: Lippincott Williams & Wilkins; 2013.

    Google Scholar 

  71. Mazzaferri EL. Management of a solitary thyroid nodule. N Engl J Med. 1993;328(8):553–9.

    Article  CAS  PubMed  Google Scholar 

  72. Saggiorato E, Angusti T, Rosas R, Martinese M, Finessi M, Arecco F, et al. 99mTc-MIBI imaging in the presurgical characterization of thyroid follicular neoplasms: relationship to multidrug resistance protein expression. J Nucl Med. 2009;50(11):1785–93.

    Article  PubMed  Google Scholar 

  73. Giovanella L, Campenni A, Treglia G, Verburg FA, Trimboli P, Ceriani L, et al. Molecular imaging with (99m)Tc-MIBI and molecular testing for mutations in differentiating benign from malignant follicular neoplasm: a prospective comparison. Eur J Nucl Med Mol Imaging. 2016;43(6):1018–26.

    Article  CAS  PubMed  Google Scholar 

  74. Campenni A, Giovanella L, Siracusa M, Alibrandi A, Pignata SA, Giovinazzo S, et al. (99m)Tc-Methoxy-isobutyl-isonitrile scintigraphy is a useful tool for assessing the risk of malignancy in thyroid nodules with indeterminate fine-needle cytology. Thyroid. 2016;26(8):1101–9.

    Article  CAS  PubMed  Google Scholar 

  75. Vriens D, de Wilt JH, van der Wilt GJ, Netea-Maier RT, Oyen WJ, de Geus-Oei LF. The role of [18F]-2-fluoro-2-deoxy-d-glucose-positron emission tomography in thyroid nodules with indeterminate fine-needle aspiration biopsy: systematic review and meta-analysis of the literature. Cancer. 2011;117(20):4582–94.

    Article  PubMed  Google Scholar 

  76. Vriens D, Adang EM, Netea-Maier RT, Smit JW, de Wilt JH, Oyen WJ, et al. Cost-effectiveness of FDG-PET/CT for cytologically indeterminate thyroid nodules: a decision analytic approach. J Clin Endocrinol Metab. 2014;99(9):3263–74.

    Article  CAS  PubMed  Google Scholar 

  77. Merten MM, Castro MR, Zhang J, Durski JM, Ryder M. Examining the role of preoperative positron emission tomography/computerized tomography (PET/CT) in combination with ultrasonography in discriminating benign from malignant cytologically indeterminate thyroid nodules. Thyroid. 2016;27(1):95–102.

    Article  PubMed  Google Scholar 

  78. Sager S, Vatankulu B, Erdogan E, Mut S, Teksoz S, Ozturk T, et al. Comparison of F-18 FDG-PET/CT and Tc-99m MIBI in the preoperative evaluation of cold thyroid nodules in the same patient group. Endocrine. 2015;50(1):138–45.

    Article  CAS  PubMed  Google Scholar 

  79. Piccardo A, Puntoni M, Treglia G, Foppiani L, Bertagna F, Paparo F, et al. Thyroid nodules with indeterminate cytology: prospective comparison between 18F-FDG-PET/CT, multiparametric neck ultrasonography, 99mTc-MIBI scintigraphy and histology. Eur J Endocrinol. 2016;174(5):693–703.

    Article  CAS  PubMed  Google Scholar 

  80. Bogsrud TV, Karantanis D, Nathan MA, Mullan BP, Wiseman GA, Collins DA, et al. The value of quantifying 18F-FDG uptake in thyroid nodules found incidentally on whole-body PET-CT. Nucl Med Commun. 2007;28(5):373–81.

    Article  PubMed  Google Scholar 

  81. Soelberg KK, Bonnema SJ, Brix TH, Hegedus L. Risk of malignancy in thyroid incidentalomas detected by 18F-fluorodeoxyglucose positron emission tomography: a systematic review. Thyroid. 2012;22(9):918–25.

    Article  CAS  PubMed  Google Scholar 

  82. Gianoukakis AG, Karam M, Cheema A, Cooper JA. Autonomous thyroid nodules visualized by positron emission tomography with 18F-fluorodeoxyglucose: a case report and review of the literature. Thyroid. 2003;13(4):395–9.

    Article  CAS  PubMed  Google Scholar 

  83. Yoon JH, Cho A, Lee HS, Kim EK, Moon HJ, Kwak JY. Thyroid incidentalomas detected on 18F-fluorodeoxyglucose-positron emission tomography/computed tomography: Thyroid Imaging Reporting and Data System (TIRADS) in the diagnosis and management of patients. Surgery. 2015;158(5):1314–22.

    Article  PubMed  Google Scholar 

  84. Hoang JK, Langer JE, Middleton WD, Wu CC, Hammers LW, Cronan JJ, et al. Managing incidental thyroid nodules detected on imaging: white paper of the ACR Incidental Thyroid Findings Committee. J Am Coll Radiol. 2015;12(2):143–50.

    Article  PubMed  Google Scholar 

  85. Treglia G, Caldarella C, Saggiorato E, Ceriani L, Orlandi F, Salvatori M, et al. Diagnostic performance of (99m)Tc-MIBI scan in predicting the malignancy of thyroid nodules: a meta-analysis. Endocrine. 2013;44(1):70–8.

    Article  CAS  PubMed  Google Scholar 

  86. Greilsamer T, Blanchard C, Christou N, Drui D, Ansquer C, Le Bras M, et al. Management of thyroid nodules incidentally discovered on MIBI scanning for primary hyperparathyroidism. Langenbeck’s Arch Surg. 2015;400(3):313–8.

    Article  Google Scholar 

  87. Aziz AL, Courbon F, Dierickx LO, Pascal P, Zerdoud S. Oncocytic adenoma of thyroid incidentally detected by 18F-Fluorocholine PET/CT. J Nucl Med Technol. 2015;43(2):133–4.

    Article  PubMed  Google Scholar 

  88. Lalire P, Zalzali M, Garbar C, Bruna-Muraille C, Morland D. Incidental detection of oxyphilic papillary thyroid carcinoma by 18F-fluorocholine PET/CT. Clin Nucl Med. 2016;41(6):512–3.

    Article  PubMed  Google Scholar 

  89. Lezaic L, Rep S, Sever MJ, Kocjan T, Hocevar M, Fettich J. (1)(8)F-Fluorocholine PET/CT for localization of hyperfunctioning parathyroid tissue in primary hyperparathyroidism: a pilot study. Eur J Nucl Med Mol Imaging. 2014;41(11):2083–9.

    Article  CAS  PubMed  Google Scholar 

  90. Michaud L, Burgess A, Huchet V, Lefevre M, Tassart M, Ohnona J, et al. Is 18F-fluorocholine-positron emission tomography/computerized tomography a new imaging tool for detecting hyperfunctioning parathyroid glands in primary or secondary hyperparathyroidism? J Clin Endocrinol Metab. 2014;99(12):4531–6.

    Article  CAS  PubMed  Google Scholar 

  91. Lincke T, Orschekowski G, Singer J, Sabri O, Paschke R. Increased gallium-68 DOTATOC uptake in normal thyroid glands. Horm Metab Res. 2011;43(4):282–6.

    Article  CAS  PubMed  Google Scholar 

  92. Versari A, Sollini M, Frasoldati A, Fraternali A, Filice A, Froio A, et al. Differentiated thyroid cancer: a new perspective with radiolabeled somatostatin analogues for imaging and treatment of patients. Thyroid. 2014;24(4):715–26.

    Article  CAS  PubMed  Google Scholar 

  93. Nockel P, Millo C, Keutgen X, Klubo-Gwiezdzinska J, Shell J, Patel D, et al. The rate and clinical significance of incidental thyroid uptake as detected by gallium-68 DOTATATE positron emission tomography/computed tomography. Thyroid. 2016;26(6):831–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

The authors want to thank Dr. Jacek Makarewicz, Dr. I Ross McDougall, and Dr. Barbara Ruszczak for their help in preparing this manuscript.

Author information

Authors and Affiliations

  1. Division of Nuclear Medicine, Department of Radiology, Mayo Clinic, Rochester, MN, 55902, USA

    Jolanta M. Durski MD

  2. Radiology and Nuclear Medicine, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway

    Trond Velde Bogsrud MD, PhD

Authors
  1. Jolanta M. Durski MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Trond Velde Bogsrud MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jolanta M. Durski MD .

Editor information

Editors and Affiliations

  1. Division of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic College of Medicine, Rochester, Minnesota, USA

    Hossein Gharib

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Cite this chapter

Durski, J.M., Bogsrud, T.V. (2018). Nuclear Medicine in Evaluation and Therapy of Nodular Thyroid. In: Gharib, H. (eds) Thyroid Nodules. Contemporary Endocrinology. Humana Press, Cham. https://doi.org/10.1007/978-3-319-59474-3_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-59474-3_4

  • Published:

  • Publisher Name: Humana Press, Cham

  • Print ISBN: 978-3-319-59473-6

  • Online ISBN: 978-3-319-59474-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation